VIVUS (VVUS), Auxilium Announce Extension of STENDRA License Termination Data
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- S&P 500 ends up slightly with boost from financials; Netflix up late
- Nestle Said Examining Takeover of Mead Johnson (MJN) - Source
- Fed's Yellen says 'makes sense' to gradually raise interest rates
- UPDATE: Fed Beige Book: Wages gain modestly in most areas amid tight job market
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc., a subsidiary of Endo International plc (Nasdaq: ENDP) announced an extension of the termination date of the license agreement between Auxilium and VIVUS for STENDRA® (avanafil) U.S. and Canadian commercial rights through September 30, 2016.
"We have been working closely with Auxilium to ensure a smooth transition of STENDRA back to VIVUS," said Seth H. Z. Fischer, VIVUS Chief Executive Officer. "Through this process, we have determined that a handoff of STENDRA at the end of a calendar quarter provides the most efficient cut-off date for our internal processes, customers and vendors. We are concurrently preparing to commercialize STENDRA in the U.S. while maintaining discussions to license or sell STENDRA's U.S. commercialization rights."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sallie Mae (SLM) Issues Statement on CFPB Complaint
- Navient (NAVI) Rejects CFPB Ultimatum to Settle
- Horizon Technology Finance (HRZN) Names Daniel Trolio as CFO
Create E-mail Alert Related CategoriesCorporate News, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!